Global Continuous Peripheral Nerve Block Catheters Market - 2023-2030

Global Continuous Peripheral Nerve Block Catheters Market - 2023-2030

Market Overview

The global Continuous Peripheral Nerve Block Catheters market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

A continuous peripheral nerve block catheter is a small tube inserted near a peripheral nerve to deliver anesthesia or pain medication directly to the nerve. This type of catheter allows for continuous medication administration over an extended period rather than receiving a single injection. It is typically used for postoperative pain management in patients who have undergone surgery on a limb or other peripheral body part.

Market Dynamics

Technological advancements drive the global Continuous Peripheral Nerve Block Catheters market growth. Continuous peripheral nerve block catheters are becoming more widely utilized, particularly in hospitals, because catheter placement can be done more precisely and is less expensive than other analgesic delivery techniques.

An increasing benefit of continuous peripheral nerve block catheters drives the market growth

Foot and ankle surgery is often associated with postoperative opioid use, which has been demonstrated to be associated with several postoperative complications. As per the article published in Case Reports in Anesthesiology in 2021, continuous peripheral nerve blocks (CPNB) are a safe and effective method of pain management for outpatient foot and ankle surgery. CPNBs have also been shown to reduce the requirement of rescue opioid use following ambulatory orthopedic surgery compared to single-shot peripheral nerve blocks (PNB). Early work has suggested that continuous peripheral nerve block catheters should be removed after 48 hours due to the increased risk of infection.

CPNBs allow for increased flexibility in the duration and intensity of blocks compared to single-shot PNBs postoperatively. Early studies have shown that the risk of infection increases following 48 hours with an indwelling peripheral nerve block catheter. A recent study reported that the likelihood of infection-free peripheral catheter decreases from 99% on day 4 to 96% on day 7 to 73% on day 15.

Depending on the surgical procedure, peripheral nerve catheters can provide complete analgesia and negate the need for additional pain relief during recovery. This may lead to improved patient satisfaction and reductions in opioid use, hospital length of stay and persistent postoperative pain. There may also be improvements in functional rehabilitation, including earlier mobilization, a greater range of joint motion and better engagement with physiotherapy.

The risk factors associated with continuous peripheral nerve block catheters will hamper the growth of the market

However, there are several potential risks associated with the use of continuous peripheral nerve block catheters. Any invasive procedure carries a risk of infection. The risk is low, but infections can occur at the site where the catheter is inserted or where the anesthesia or pain medication is delivered. The catheter could cause damage to the nerve it is near, which can lead to pain, numbness or weakness in the affected limb. Blood clots can form in the limb where the catheter is inserted, which can be life-threatening if they travel to the lungs. Overdose is a risk with any pain medication, and the continuous administration of medication through a catheter can increase the risk. Some people may have an allergic reaction to the medication being administered through the catheter. The catheter may become dislodged, which can cause pain, bleeding, or decreased effectiveness of the anesthesia or pain medication.

COVID-19 Impact Analysis

The COVID-19 pandemic has particularly impacted the continuous peripheral nerve block catheters market. Due to the pandemic, elective surgeries, which account for a significant portion of the market for these catheters, have been delayed or canceled. This has led to a reduction in demand for these catheters. As per the article published in The Canadian Journal of Anesthesia in 2021, the COVID-19 pandemic caused by the SARS-CoV-2 virus has challenged society and healthcare systems. The early response to the pandemic necessitated canceling many elective and non-urgent surgeries. It is estimated that more than 28 million adult elective surgical procedures were canceled worldwide during the first 12 weeks of peak disruption due to the COVID‐19 pandemic. This response was to conserve hospital resources needed to manage patients with SARS-CoV-2 infection.

Additionally, supply chain disruptions and decreased disposable income among individuals have also contributed to the decrease in demand for these catheters. However, as the pandemic continues, the market for these catheters will likely recover as elective surgeries resume and supply chain disruptions are resolved.

Segment Analysis

The pain management segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pain management segment accounts for the highest market share. As an efficient and secure alternative to opioid painkillers, a continuous catheter nerve block, also known as a continuous peripheral nerve block, aids in the management of chronic pain. The nerve block often has fewer side effects while effectively reducing the requirement for high dosages of oral painkillers. Once the catheter is in place, the patient can utilize it to manage their pain over the long term.

A catheter is a narrow, flexible plastic tube inserted beneath the skin close to the pain-causing peripheral nerve. To assist in controlling the pain, the catheter continuously administers painkillers to the affected portion of the body.

Alternatives to opioid medicines, which carry the danger of misuse, dependence, and potential overdose, include continuous catheter nerve blocks. The nerve block is a technique for maximizing sensory blocking with the least lingering motor blocking.

Geographical Analysis

North America region holds the largest market share of the global continuous peripheral nerve block catheters market

North America dominates the market for continuous peripheral nerve block catheters and is expected to show a similar trend over the forecast period. Technological advancements drive the market, an increasing number of knee replacement surgeries, and product launches by market players in the North American region.

As per the article published in Cureus Journal in 2022, total knee replacement (TKR) is a commonly performed procedure, with up to one million TKRs performed annually in the US. It is expected to increase to 3.5 million per year in 2030. This procedure is associated with significant postoperative pain. Postoperative pain relief is a major determinant of a patient’s satisfaction with treatment in addition to the physiological ill effects. Postoperative pain relief is also important because inadequately treated acute pain may lead to chronic pain.

An alternative to epidural analgesia is peripheral nerve blockade of the femoral nerve using catheters for continuous infiltration, also called continuous perineural blockade (CPNB). The increasing knee replacement procedures lead to increasing demand for continuous peripheral nerve block catheter markets in the North American region.

Competitive Landscape

The continuous peripheral nerve block catheters market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Ambu A/S, Teleflex Incorporated, B. Braun Melsungen AG, Smiths Group plc, Halyard Health, Pajunk GmbH, EPIMED INTERNATIONAL, Ace Medical, Lepu Medical Technology Co.,Ltd and Vygon, among others. The major players are adopting several growth strategies, such as Type launches, acquisitions, and collaborations, contributing to the growth of the continuous peripheral nerve block catheters market globally.

For instance,
• In February 2022, InfuSystem Holdings, Inc., a leading national healthcare service provider facilitating outpatient care for durable medical equipment manufacturers and healthcare providers, agreed with Solo-Dex, Inc. for its proprietary continuous nerve block catheter distribution.

Teleflex Incorporated

Overview:

Teleflex is a medical technology company designed to improve the health and quality of people’s lives. The company provides a broad portfolio with solutions in vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.

Product Portfolio:

Arrow StimuCath Continuous Nerve block kits: Arrow Anesthesiologists who use stimulation, ultrasound, or a combination of both to place StimuCath Continuous Nerve block kits cater to peripheral nerve blocks. During ultrasonography-assisted treatments, StimuCath's distinctive stainless steel coil tip permits catheter stimulation to confirm insertion close to the nerves and offers greater visibility.

The global continuous peripheral nerve block catheters market report would provide access to approximately 60+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.